Renal Impairment Clinical Trial
Official title:
A Phase 1, Multi-center, Open-label, Single-dose Study to Assess the Pharmacokinetics of Mezigdomide (BMS-986348, CC-92480) in Adult Participants With Normal Renal Function, Severe Renal Impairment, and End-stage Renal Disease
The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.
| Status | Not yet recruiting |
| Enrollment | 32 |
| Est. completion date | March 5, 2025 |
| Est. primary completion date | March 5, 2025 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 82 Years |
| Eligibility | Inclusion Criteria - Participants must have a body mass index (BMI) of = 18.0 kg/m2 to = 40.0 kg/m2 inclusive at screening. - Participants must have a body weight = 50 kg at screening. - Participants must be afebrile (febrile is defined as = 38°C or 100.4°F) at screening, check in, and predose. Exclusion Criteria - Participants must not have any history of chronic pruritus or dermatologic syndromes that may be confounded with reactions to mezigdomide. - Participants must not have any history of malignancy of any type other than in situ cervical cancer or surgically excised non-melanomatous skin cancers. - Participants with an inability to tolerate oral medication. - Other protocol-defined Inclusion/Exclusion criteria apply. |
| Country | Name | City | State |
|---|---|---|---|
| United States | PANAX | Miami Lakes | Florida |
| United States | Local Institution - 0003 | Orlando | Florida |
| United States | Orlando Clinical Research Center OCRC | Orlando | Florida |
| Lead Sponsor | Collaborator |
|---|---|
| Celgene |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Maximum observed concentration (Cmax) | Up to 24 days | ||
| Primary | Area under the plasma concentration-time curve (AUC) | Up to 24 days | ||
| Primary | Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration (AUC(0-T)) | Up to 24 days | ||
| Secondary | Number of participants with adverse events (AEs) | Up to 54 days | ||
| Secondary | Number of participants with serious adverse events (SAEs) | Up to 54 days | ||
| Secondary | Number of participants with physical examination findings | Up to 24 days | ||
| Secondary | Number of participants with vital sign abnormalities | Up to 24 days | ||
| Secondary | Number of participants with 12-lead electrocardiogram (ECG) findings | Up to 24 days | ||
| Secondary | Maximum observed concentration (Cmax) | Up to 24 days | ||
| Secondary | Time of maximum observed concentration (Tmax) | Up to 24 days | ||
| Secondary | Area under the plasma concentration-time curve (AUC) | Up to 24 days |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01937975 -
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
|
Phase 1 | |
| Completed |
NCT03284164 -
Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex
|
Phase 1 | |
| Completed |
NCT05992155 -
A Study of TAK-279 in Adults With or Without Kidney Problems
|
Phase 1 | |
| Completed |
NCT05004311 -
The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT04963738 -
A Study of JNJ-73763989 in Adult Participants With Renal Impairment
|
Phase 1 | |
| Terminated |
NCT02508740 -
Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment
|
Phase 1 | |
| Active, not recruiting |
NCT01529658 -
Renal Hypothermia During Partial Nephrectomy
|
N/A | |
| Terminated |
NCT00984113 -
Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment
|
Phase 1 | |
| Completed |
NCT00842868 -
The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases
|
N/A | |
| Completed |
NCT00750620 -
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
|
Phase 1 | |
| Completed |
NCT00499187 -
Fanconi Syndrome Due to ARVs in HIV-Infected Persons
|
Phase 4 | |
| Completed |
NCT01331941 -
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
|
Phase 1 | |
| Completed |
NCT05489614 -
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
|
Phase 1 | |
| Completed |
NCT03259087 -
Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)
|
Phase 1 | |
| Completed |
NCT05086107 -
Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
|
Phase 1 | |
| Recruiting |
NCT05349851 -
Bowel Cleansing With Renal Impairment
|
||
| Completed |
NCT03660241 -
A Renal Impairment Study for PF-04965842
|
Phase 1 | |
| Recruiting |
NCT06037031 -
A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function
|
Phase 1 | |
| Completed |
NCT03289208 -
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment
|
Phase 1 | |
| Completed |
NCT02942810 -
To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment
|
Phase 1 |